Literature DB >> 22681682

Pharmacogenomics and personalized medicine in neuropsychiatry.

Francis J McMahon1, Thomas R Insel.   

Abstract

Despite the need for more effective treatments for psychiatric disorders, development of new medications has stalled. Here we discuss the promise of personalized medicine in developing more efficacious and individualized pharmacotherapies that take into account genetic variation and target groups of patients who share biology, not just symptoms.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22681682      PMCID： PMC3407812          DOI： 10.1016/j.neuron.2012.05.004

Source DB:  PubMed          Journal:  Neuron        ISSN： 0896-6273            Impact factor:   17.173


  19 in total

1.  Medicine. What are the right targets for psychopharmacology?

Authors:  Steven E Hyman; Wayne S Fenton
Journal:  Science       Date:  2003-01-17       Impact factor: 47.728

Review 2.  Genomic medicine--an updated primer.

Authors:  W Gregory Feero; Alan E Guttmacher; Francis S Collins
Journal:  N Engl J Med       Date:  2010-05-27       Impact factor: 91.245

Review 3.  The impact of CYP allelic variation on antidepressant metabolism: a review.

Authors:  John L Black; Dennis J O'Kane; David A Mrazek
Journal:  Expert Opin Drug Metab Toxicol       Date:  2007-02       Impact factor: 4.481

Review 4.  Lessons from 60 years of pharmaceutical innovation.

Authors:  Bernard Munos
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

5.  Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment.

Authors:  Francis J McMahon; Silvia Buervenich; Dennis Charney; Robert Lipsky; A John Rush; Alexander F Wilson; Alexa J M Sorant; George J Papanicolaou; Gonzalo Laje; Maurizio Fava; Madhukar H Trivedi; Stephen R Wisniewski; Husseini Manji
Journal:  Am J Hum Genet       Date:  2006-03-20       Impact factor: 11.025

6.  Training in psychiatric genomics during residency: a new challenge.

Authors:  Joel G Winner; Deborah Goebert; Courtenay Matsu; David A Mrazek
Journal:  Acad Psychiatry       Date:  2010 Mar-Apr

7.  Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment.

Authors:  Elisabeth B Binder; Daria Salyakina; Peter Lichtner; Gabriele M Wochnik; Marcus Ising; Benno Pütz; Sergi Papiol; Shaun Seaman; Susanne Lucae; Martin A Kohli; Thomas Nickel; Heike E Künzel; Brigitte Fuchs; Matthias Majer; Andrea Pfennig; Nikola Kern; Jürgen Brunner; Sieglinde Modell; Thomas Baghai; Tobias Deiml; Peter Zill; Brigitta Bondy; Rainer Rupprecht; Thomas Messer; Oliver Köhnlein; Heike Dabitz; Tanja Brückl; Nina Müller; Hildegard Pfister; Roselind Lieb; Jakob C Mueller; Elin Lõhmussaar; Tim M Strom; Thomas Bettecken; Thomas Meitinger; Manfred Uhr; Theo Rein; Florian Holsboer; Bertram Muller-Myhsok
Journal:  Nat Genet       Date:  2004-11-21       Impact factor: 38.330

Review 8.  Number needed to screen: development of a statistic for disease screening.

Authors:  C M Rembold
Journal:  BMJ       Date:  1998-08-01

9.  Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression.

Authors:  Manfred Uhr; Alina Tontsch; Christian Namendorf; Stephan Ripke; Susanne Lucae; Marcus Ising; Tatjana Dose; Martin Ebinger; Marcus Rosenhagen; Martin Kohli; Stefan Kloiber; Daria Salyakina; Thomas Bettecken; Michael Specht; Benno Pütz; Elisabeth B Binder; Bertram Müller-Myhsok; Florian Holsboer
Journal:  Neuron       Date:  2008-01-24       Impact factor: 17.173

10.  Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors.

Authors: 
Journal:  Genet Med       Date:  2007-12       Impact factor: 8.822
View more
  22 in total

1.  Can adaptive treatment improve outcomes in family-based therapy for adolescents with anorexia nervosa? Feasibility and treatment effects of a multi-site treatment study.

Authors:  James Lock; Daniel Le Grange; W Stewart Agras; Kathleen Kara Fitzpatrick; Booil Jo; Erin Accurso; Sarah Forsberg; Kristen Anderson; Kate Arnow; Maya Stainer
Journal:  Behav Res Ther       Date:  2015-08-01

2.  GlyT-1 Inhibition Attenuates Attentional But Not Learning or Motivational Deficits of the Sp4 Hypomorphic Mouse Model Relevant to Psychiatric Disorders.

Authors:  Jared W Young; Mary E Kamenski; Kerin K Higa; Gregory A Light; Mark A Geyer; Xianjin Zhou
Journal:  Neuropsychopharmacology       Date:  2015-04-24       Impact factor: 7.853

3.  Catehol-o-methyltransferase gene Val158met polymorphism as a potential predictor of response to computer-assisted delivery of cognitive-behavioral therapy among cocaine-dependent individuals: Preliminary findings from a randomized controlled trial.

Authors:  Kathleen M Carroll; Aryeh Herman; Elise E DeVito; Tami L Frankforter; Marc N Potenza; Mehmet Sofuoglu
Journal:  Am J Addict       Date:  2015-05-01

Review 4.  The Role of Pharmacogenomics in Bipolar Disorder: Moving Towards Precision Medicine.

Authors:  Claudia Pisanu; Urs Heilbronner; Alessio Squassina
Journal:  Mol Diagn Ther       Date:  2018-08       Impact factor: 4.074

5.  Real-time particle-by-particle detection of erythrocyte-camouflaged microsensor with extended circulation time in the bloodstream.

Authors:  Wenjun Di; Xuefei Tan; Isen Andrew C Calderon; Ashlyn E Neal Reilly; Mark Niedre; Heather A Clark
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-04       Impact factor: 11.205

Review 6.  Different Paths to Core Pathology: The Equifinal Model of the Schizophrenia Syndrome.

Authors:  Isobel W Green; Jill R Glausier
Journal:  Schizophr Bull       Date:  2015-09-20       Impact factor: 9.306

7.  Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation.

Authors:  Li-Shiun Chen; Timothy B Baker; Douglas Jorenby; Megan Piper; Nancy Saccone; Eric Johnson; Naomi Breslau; Dorothy Hatsukami; Robert M Carney; Laura J Bierut
Journal:  Drug Alcohol Depend       Date:  2015-06-23       Impact factor: 4.492

8.  Variant GADL1 and response to lithium in bipolar I disorder.

Authors:  Liping Hou; Urs Heilbronner; Marcella Rietschel; Tadafumi Kato; Po-Hsiu Kuo; Francis J McMahon; Thomas G Schulze
Journal:  N Engl J Med       Date:  2014-05-08       Impact factor: 91.245

Review 9.  Patient heal thyself: modeling and treating neurological disorders using patient-derived stem cells.

Authors:  Kevin C Ess
Journal:  Exp Biol Med (Maywood)       Date:  2013-03

Review 10.  Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How.

Authors:  Li-Shiun Chen; Laurie Zawertailo; Thomas M Piasecki; Jaakko Kaprio; Marilyn Foreman; Hannah R Elliott; Sean P David; Andrew W Bergen; James W Baurley; Rachel F Tyndale; Timothy B Baker; Laura J Bierut; Nancy L Saccone
Journal:  Nicotine Tob Res       Date:  2018-03-06       Impact factor: 4.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.